Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

120 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Potent antibody drug conjugates for cancer therapy.
Senter PD. Senter PD. Curr Opin Chem Biol. 2009 Jun;13(3):235-44. doi: 10.1016/j.cbpa.2009.03.023. Epub 2009 May 4. Curr Opin Chem Biol. 2009. PMID: 19414278 Review.
Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Leal M, et al. Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Ann N Y Acad Sci. 2014. PMID: 25123209 Review.
Antibody-drug conjugates: targeted drug delivery for cancer.
Alley SC, Okeley NM, Senter PD. Alley SC, et al. Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17. Curr Opin Chem Biol. 2010. PMID: 20643572 Review.
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC. Burke PJ, et al. Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4. Mol Cancer Ther. 2016. PMID: 26944920
Development of orally active inhibitors of protein and cellular fucosylation.
Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law CL, Sussman D, Toki BE, Westendorf L, Zeng W, Zhang X, Benjamin DR, Senter PD. Okeley NM, et al. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. doi: 10.1073/pnas.1222263110. Epub 2013 Mar 14. Proc Natl Acad Sci U S A. 2013. PMID: 23493549 Free PMC article.
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA. Kung Sutherland MS, et al. Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14. Blood. 2013. PMID: 23770776
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
Neumann CS, Olivas KC, Anderson ME, Cochran JH, Jin S, Li F, Loftus LV, Meyer DW, Neale J, Nix JC, Pittman PG, Simmons JK, Ulrich ML, Waight AB, Wong A, Zaval MC, Zeng W, Lyon RP, Senter PD. Neumann CS, et al. Among authors: senter pd. Mol Cancer Ther. 2018 Dec;17(12):2633-2642. doi: 10.1158/1535-7163.MCT-18-0643. Epub 2018 Sep 21. Mol Cancer Ther. 2018. PMID: 30242091 Free article.
Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models.
Burke PJ, Hamilton JZ, Pires TA, Lai HWH, Leiske CI, Emmerton KK, Waight AB, Senter PD, Lyon RP, Jeffrey SC. Burke PJ, et al. Among authors: senter pd. Mol Cancer Ther. 2018 Aug;17(8):1752-1760. doi: 10.1158/1535-7163.MCT-18-0073. Epub 2018 Jun 4. Mol Cancer Ther. 2018. PMID: 29866744 Free article.
120 results
Jump to page
Feedback